Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
Low-risk prostate adenocarcinoma is classically managed either with active surveillance or radical therapy (such as external radiotherapy or radical prostatectomy), but both have significant side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy proposed as an alternative approach for localized, low-volume, and low-Gleason score (≤6) carcinomas. We report histological modifications observed in prostate biopsies of 56 patients, performed 6 months after VTP using the photosensitizer TOOKAD® Soluble (WST11) and low-energy laser administered in the tumor area transperineally by optic fibers. In 53 patients, we observed sharply demarcated hyaline fibrotic scars, with or without rare atrophic glands, sometimes reduced to corpora amylacea surrounded by giant multinuclear macrophages. Mild chronic inflammation, hemosiderin, and coagulative necrosis were also observed. When residual cancer was present in a treated lobe (17 patients), it was always located outside the scar, most often close to the prostate capsule, and it showed no therapy-related modification. Histopathological interpretation of post-WST11 VTP prostate biopsies was straightforward, in contrast with that of prostate biopsies after radio or hormonal therapy, which introduces lesions difficult to interpret. VTP resulted in complete ablation of cancer in the targeted area.
Cellular and Tissue Pathology Department, LUNAM University, CHU University Hospital, Angers, France.
Caroline
C
Eymerit-Morin
Merzouka
M
Zidane
Souhil
S
Lebdai
Stéphane
S
Triau
Abdel Rahmene
AR
Azzouzi
Marie-Christine
MC
Rousselet
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology*; D000368:Aged; D001429:Bacteriochlorophylls / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D001429:Bacteriochlorophylls; D017319:Photosensitizing Agents; C503696:padeliporfin